Abstract:
Long interspersed element-1 (LINE-1), which is the only autonomous retrotransposon in human genome, makes up about 17% of the human genome. For LINE-1 retrotransposition may result in genome instability, it was strictly restricted by organisms, and its expression was therefore barely detected in normal somatic cells. However, the expression of LINE-1 is a common phenomenon in most tumor or cancer tissues, suggesting a close relationship between LINE-1 expression and cancer development. Differentially expressed LINE-1 in cancer tissues can be used as a biomarker for tumor diagnosis and an important indicator of prognosis after cancer therapeutics. Meanwhile, the feasibility of LINE-1 as a potential drug target for tumor treatment has also been evaluating and verifying in clinicals. In this review, we introduce the application of LINE-1 as a biomarker in tumor diagnosis and prognostic, as well as the research progress in LINE-1 as potential drug target for tumor treatment, in order to provide some references for clinical application in cancer treatment.
长散布元件-1 (long interspersed elements-1, LINE-1)约占人类基因组的17%,是人类基因组中唯一具有自主转座能力的转座子。LINE-1可通过逆转录转座过程插入到新的基因位点上,从而会导致基因组的不稳定。因而机体对LINE-1的复制和转座有着严格的限制,在正常体细胞中几乎检测不到LINE-1的表达。然而,在绝大多数的肿瘤组织或癌组织中LINE-1的表达却普遍存在,提示LINE-1的表达和转座与肿瘤的发生发展密切相关。LINE-1在肿瘤细胞中的差异表达可以作为肿瘤早期诊断的标志物,同时也可作为肿瘤治疗预后评价的重要指标。与此同时,LINE-1作为肿瘤治疗潜在靶点的可行性也在评估和验证中。本文介绍了在临床方面LINE-1作为肿瘤诊断、预后方面的应用,以及作为肿瘤治疗潜在靶点的研究进展,以期为临床上肿瘤的诊断和治疗提供一些参考。.